Ophthalmology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
Ophthalmology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
BMJ Case Rep. 2020 Nov 3;13(11):e235102. doi: 10.1136/bcr-2020-235102.
A 59-year-old man with diabetic macular oedema was treated with a dexamethasone intravitreal implant (Ozurdex) to his right eye. Immediately after injection, the implant was noted to have extruded into the perilimbal subconjunctival space. The remnants of the implant were expeditiously removed the following day to avoid corneal decompensation and permanent corneal oedema. Endothelial decompensation secondary to the migration of dexamethasone implants into the subconjunctival space or anterior chamber is a recognised complication of Ozurdex injection. The patient recovered well postoperatively with no further complications. He was planned for a new Ozurdex implant 1 month later.
一位 59 岁男性，患有糖尿病性黄斑水肿，右眼接受了地塞米松玻璃体内植入物（Ozurdex）治疗。注射后立即发现植入物挤出到角膜缘周围的结膜下间隙。为了避免角膜失代偿和永久性角膜水肿，第二天迅速将植入物的残留物取出。地塞米松植入物迁移到结膜下或前房引起的内皮失代偿是 Ozurdex 注射的一种公认并发症。患者术后恢复良好，无其他并发症。计划 1 个月后再次进行 Ozurdex 植入。
